<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">surgonco</journal-id><journal-title-group><journal-title xml:lang="ru">Креативная хирургия и онкология</journal-title><trans-title-group xml:lang="en"><trans-title>Creative surgery and oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2076-3093</issn><issn pub-type="epub">2307-0501</issn><publisher><publisher-name>Башкирский государственный медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24060/2076-3093-10-3-205-211</article-id><article-id custom-type="elpub" pub-id-type="custom">surgonco-506</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Эмболизация почечной артерии в комбинированном лечении больных раком почки IV стадии</article-title><trans-title-group xml:lang="en"><trans-title>Embolization of the Renal Artery in Combined Treatment of Stage IV Kidney Cancer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2047-963X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ганцев</surname><given-names>Ш. Х.</given-names></name><name name-style="western" xml:lang="en"><surname>Gantsev</surname><given-names>Sh. Kh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, кафедра онкологии с курсами онкологии и патологической анатомии ИДПО,</p><p>Республика Башкортостан, Уфа</p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), Prof., Department of Oncology with Courses of Oncology and Pathological Anatomy for Advanced Professional Education,</p><p>Ufa</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юн</surname><given-names>В.</given-names></name><name name-style="western" xml:lang="en"><surname>Yun</surname><given-names>V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра онкологии с курсами онкологии и патологической анатомии ИДПО,</p><p>Республика Башкортостан, Уфа</p></bio><bio xml:lang="en"><p>Department of Oncology with Courses of Oncology and Pathological Anatomy for Advanced Professional Education,</p><p> Ufa</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жумагулова</surname><given-names>А. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhumagulova</surname><given-names>A. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>отделение химиотерапии,</p><p>Туркестан,</p><p>Шымкент</p></bio><bio xml:lang="en"><p>Department of Chemotherapy,</p><p>Shymkent</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0237-9064</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Арыбжанов</surname><given-names>Д. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Arybzhanov</surname><given-names>D. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., отделение химиотерапии, кафедра хирургических дисциплин № 1,</p><p>Шымкент</p></bio><bio xml:lang="en"><p>Cand. Sci. (Med.), Department of Chemotherapy, Department of Surgical Disciplines No. 1, </p><p>Shymkent</p></bio><email xlink:type="simple">davran_a@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4069-6594</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Турсуметов</surname><given-names>Д. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Tursumetov</surname><given-names>D. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., кафедра онкологии с курсами онкологии и патологической анатомии ИДПО,</p><p>Республика Башкортостан, Уфа</p></bio><bio xml:lang="en"><p>Cand. Sci. (Med.), Department of Oncology with Courses of Oncology and Pathological Anatomy for Advanced Professional Education,</p><p>Ufa</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Башкирский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bashkir State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Международный казахско-турецкий университет им. Х.А. Ясави;&#13;
Городской онкологический центр</institution><country>Казахстан</country></aff><aff xml:lang="en"><institution>Akhmet Yassawi International Kazakh-Turkish University;&#13;
Shymkent City Cancer Centre</institution><country>Kazakhstan</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Южно-Казахстанская медицинская академия;&#13;
Городской онкологический центр</institution><country>Россия</country></aff><aff xml:lang="en"><institution>South Kazakhstan Medical Academy;&#13;
Shymkent City Cancer Centre</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>30</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>3</issue><fpage>205</fpage><lpage>211</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ганцев Ш.Х., Юн В., Жумагулова А.К., Арыбжанов Д.Т., Турсуметов Д.С., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Ганцев Ш.Х., Юн В., Жумагулова А.К., Арыбжанов Д.Т., Турсуметов Д.С.</copyright-holder><copyright-holder xml:lang="en">Gantsev S.K., Yun V., Zhumagulova A.K., Arybzhanov D.T., Tursumetov D.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.surgonco.ru/jour/article/view/506">https://www.surgonco.ru/jour/article/view/506</self-uri><abstract><sec><title>Введение</title><p>Введение. Рак почки остается актуальной проблемой современной онкологии. Ежегодно в мире выявляются более 200  тыс. новых случаев рака почки и  умирают около 100  тыс. больных. 15–17% больных раком почки выявляются в IV стадии. В качестве паллиативного метода лечения используют артериальную эмболизацию опухоли и нефрэктомию.</p></sec><sec><title>Цель исследования</title><p>Цель исследования: оценить результаты эмболизации почечной артерии при комбинированном лечении больных раком почки IV стадии. Материал и методы.Представлены результаты лечения 22 пациентов с раком почки IV стадии: 6 пациентов имели метастазы в кости скелета, 15 — метастазы в легких, одна пациентка — двухстороннее поражение почек. Всем пациентам на  первом этапе произведена эмболизация почечной артерии, далее 6  пациентов получили лучевую терапию на метастазы в костях скелета и бисфосфонаты, 15 больных после эмболизации прооперированы + прием таргетной терапии (Сунитиниб, Сорафениб), а пациентка с двухсторонним поражением почек после эмболизации оперирована и 2 года получала таргетную терапию Сорафенибом.</p><p>Результаты и их обсуждение. Эмболизации почечной артерии всем больным была выполнена успешно без технических трудностей. После эмболизации у всех пациентов с гематурией (n = 14) был достигнут гемостаз. У 13 пациентов с тотальной эмболизацией почечной артерии отмечался постэмболизационный синдром. 6 пациентов с метастазами в кости скелета прожили 16,4 ± 2,1 месяца, время дожития 15 пациентов, получивших эмболизацию почечной артерии, нефрэктомию и таргетную терапию, составило 41,7 ± 15,3 месяца. Только одна пациентка с двухсторонним поражением почек находится под динамическим наблюдением до настоящего времени (продолжительность жизни составила более 10 лет).</p></sec><sec><title>Заключение</title><p>Заключение. Эмболизация почечной артерии — эффективная и малоинвазивная техническая процедура, которая должна использоваться в комбинированном лечении пациентов с раком почки. Сочетанное применение эмболизации почечной артерии и последующей таргетной терапии при раке почки дает новые возможности комбинированного лечения IV стадии. </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Kidney cancer remains an urgent problem in modern oncology. More than 200 thousand new cases of kidney cancer are diagnosed globally every year, with about 100 thousand patients dying. 15–17% of patients are diagnosed with stage IV kidney cancer. Arterial tumour embolization and nephrectomy are used as a palliative treatment.</p></sec><sec><title>Aim</title><p>Aim. To evaluate the results of renal artery embolization in combined treatment of stage IV kidney cancer.</p></sec><sec><title>Material and methods</title><p>Material and methods. The treatment results of 22 patients with stage IV kidney cancer are presented: 6 patients had metastases in the skeletal bones; 15 — metastases in the lungs; 1 — bilateral kidney damage. At the first stage, all patients underwent renal artery embolization. Subsequently, 6 patients received bisphosphonates and radiation therapy for metastases in the skeletal bones, 15 patients underwent operation followed by a targeted therapy with Sunitinib and Sorafenib), 1 patient with bilateral kidney damage underwent operation followed by a 2-year targeted therapy with Sorafenib.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. Renal artery embolization was performed successfully without technical difficulties in all the patients. After embolization, hemostasis was achieved in all patients with hematuria (n = 14). Postembolization syndrome was noted in 13 patients with total renal artery embolization. 6 patients with metastases in the skeletal bones lived for 16.4 ± 2.1 months, the survival time of 15 patients who received renal artery embolization, nephrectomy and targeted therapy was 41.7 ± 15.3 months. Only one patient (bilateral kidney damage) has been under dynamic observation for the period of 10 years.</p></sec><sec><title>Conclusion</title><p>Conclusion. Renal artery embolization is an effective and minimally invasive technical procedure that should be used in the combined treatment of patients with kidney cancer. The combined use of renal artery embolization and subsequent targeted therapy for kidney cancer provide new opportunities for stage IV combined treatment. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рак почек</kwd><kwd>эмболизация почечной артерии</kwd><kwd>метастазы</kwd><kwd>лучевая терапия</kwd><kwd>таргетная терапия</kwd><kwd>выживаемость</kwd></kwd-group><kwd-group xml:lang="en"><kwd>renal cancer</kwd><kwd>renal artery embolization</kwd><kwd>metastases</kwd><kwd>radiation therapy</kwd><kwd>targeted therapy</kwd><kwd>survival rate</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., et al. (editors) GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 v1.0. In: IARC CancerBase No. 11. Available from: http://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-AndPrevalence-Worldwide-In-2012-V1.0-2012</mixed-citation><mixed-citation xml:lang="en">Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., et al. (editors) GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 v1.0. In: IARC CancerBase No. 11. Available from: http://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-IncidenceMortality-And-Prevalence-Worldwide-In-2012-V1.0-2012</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">CI5Plus: Cancer incidence in five continents time trends. In: International Agency for Research on Cancer. Available from: http://ci5.iarc.fr/CI5plus/Default.aspx</mixed-citation><mixed-citation xml:lang="en">CI5Plus: Cancer incidence in five continents time trends. In: International Agency for Research on Cancer. Available from: http://ci5.iarc.fr/CI5plus/Default.aspx</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Scelo G., Li P., Chanudet E., Muller D.C. Variability of sex disparities in cancer incidence over 30 years: the striking case of kidney cancer. Eur Urol Focus. 2018;4(4):586–90. DOI: 10.1016/j.euf.2017.01.006</mixed-citation><mixed-citation xml:lang="en">Scelo G., Li P., Chanudet E., Muller D.C. Variability of sex disparities in cancer incidence over 30 years: the striking case of kidney cancer. Eur Urol Focus. 2018;4(4):586–90. DOI: 10.1016/j.euf.2017.01.006</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Li P., Znaor A., Holcatova I., Fabianova E., Mates D., Wozniak M.B., et al. Regional geographic variations in kidney cancer incidence rates in European countries. Eur Urol. 2015;67(6):1134–41. DOI: 10.1016/j.eururo.2014.11.001</mixed-citation><mixed-citation xml:lang="en">Li P., Znaor A., Holcatova I., Fabianova E., Mates D., Wozniak M.B., et al. Regional geographic variations in kidney cancer incidence rates in European countries. Eur Urol. 2015;67(6):1134–41. DOI: 10.1016/j.eururo.2014.11.001</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России; 2018. 250 с.</mixed-citation><mixed-citation xml:lang="en">Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant neoplasms in Russia in 2016 (morbidity and mortality). Moscow: P.A. Herzen Moscow Oncology Research Centre; 2018. 250 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Кайдарова Д.Р. Показатели онкологической службы республики Казахстан за 2019 год (статистические и аналитические материалы). Алматы; 2020. 137 с.</mixed-citation><mixed-citation xml:lang="en">Kaydarova D.R. Indicators of oncology service of the Republic of Kazakhstan for 2019 (statistical data and analytical materials). Almaty; 2020. 137 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Лидерман Е.М., Забелин М.В. Анализ экологических условий обусловленности здоровья населения Южного федерального округа в аспекте организации региональной системы медикосоциальной реабилитации. Здравоохранение, образование и безопасность. 2018;(1):7–20.</mixed-citation><mixed-citation xml:lang="en">Liderman E.M., Zabelin M.V. Analysis of ecological conditions of conditionality of the population health in the Southern Federal District in aspect of the organization of the regional system of medico-social rehabilitation. Healthcare, education and security. 2018;(1):7–20 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zielinski H., Syrylo T., Szmigielski S. Renal artery embolization in treatment of renal cancer with emphasis on response of immune system. In: Jindong Chen (editor) Renal Tumor. London: IntechOpen; 2013. DOI: 10.5772/54116</mixed-citation><mixed-citation xml:lang="en">Zielinski H., Syrylo T., Szmigielski S. Renal artery embolization in treatment of renal cancer with emphasis on response of immune system. In: Jindong Chen (editor) Renal Tumor. London: IntechOpen; 2013. DOI: 10.5772/54116</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Jonasch E. Updates to the management of kidney cancer. J Natl Compr Canc Netw. 2018;16(5S):639–41. DOI: 10.6004/jnccn.2018.0039</mixed-citation><mixed-citation xml:lang="en">Jonasch E. Updates to the management of kidney cancer. J Natl Compr Canc Netw. 2018;16(5S):639–41. DOI: 10.6004/jnccn.2018.0039</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Dabestani S., Marconi L., Kuusk T., Bex A. Follow-up after curative treatment of localised renal cell carcinoma. World J Urol. 2018;36(12):1953–9. DOI: 10.1007/s00345-018-2338-z</mixed-citation><mixed-citation xml:lang="en">Dabestani S., Marconi L., Kuusk T., Bex A. Follow-up after curative treatment of localised renal cell carcinoma. World J Urol. 2018;36(12):1953–9. DOI: 10.1007/s00345-018-2338-z</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Биткина Т.А., Басевич А.В., Родин В.М. Критические точки производства полимерных микросфер, используемых в рентгенохирургии. Разработка и регистрация лекарственных средств. 2020;9(3):28–35. DOI: 10.33380/2305-2066-2020-9-3-28-35</mixed-citation><mixed-citation xml:lang="en">Bitkina T.A., Basevich A.V., Rodin V.M. Critical points for the production of polymeric microspheres used in X-ray surgery. Drug development &amp; registration. 2020;9(3):28–35 (In Russ.). DOI: 10.33380/2305-2066-2020-9-3-28-35</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ураков А.Л., Уракова Н.А., Ловцова Л.В., Сорокина Ю.А., Занозина О.В. Осмотическая активность и безопасность инъекционных форм нестероидных противовоспалительных препаратов. Экспериментальная и клиническая фармакология. 2018;81(10):15–9. DOI: 10.30906/0869-2092-2018-81-10-15-19</mixed-citation><mixed-citation xml:lang="en">Urakov A.L., Urakova N.A., Lovtsova L.V., Sorokina Yu.A., Zanozina O.V. Osmotic activity and safety of non-steroidal anti-inflammatory drugs in injection medicinal forms. Experimental and Clinical Pharmacology. 2018;81(10):15–9 (In Russ.). DOI: 10.30906/0869-2092-2018-81-10-15-19</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">World Cancer Research Fund International/American Institute for Cancer Research. Continuous update project report: diet, nutrition, physical activity and kidney cancer. 2015. Available at: wcrf.org/kidneycancer-2015</mixed-citation><mixed-citation xml:lang="en">World Cancer Research Fund International/American Institute for Cancer Research. Continuous update project report: diet, nutrition, physical activity and kidney cancer. 2015. Available at: wcrf.org/ kidney-cancer-2015</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Stevens V.L., Jacobs E.J., Patel A.V., Sun J., McCullough M.L., Campbell P.T., et al. Weight cycling and cancer incidence in a large prospective US cohort. Am J Epidemiol. 2015;182(5):394–404. DOI: 10.1093/aje/kwv073</mixed-citation><mixed-citation xml:lang="en">Stevens V.L., Jacobs E.J., Patel A.V., Sun J., McCullough M.L., Campbell P.T., et al. Weight cycling and cancer incidence in a large prospective US cohort. Am J Epidemiol. 2015;182(5):394–404. DOI: 10.1093/aje/kwv073</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kaisary A.V., Williams G., Riddle P.R. The role of preoperative embolization in renal cell carcinoma. J Urol. 1984;131(4):641–6. DOI: 10.1016/s0022-5347(17)50556-x</mixed-citation><mixed-citation xml:lang="en">Kaisary A.V., Williams G., Riddle P.R. The role of preoperative embolization in renal cell carcinoma. J Urol. 1984;131(4):641–6. DOI: 10.1016/s0022-5347(17)50556-x</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Bakal C.W., Cynamon J., Lakritz P.S., Sprayregen S. Value of preoperative renal artery embolization in reducing blood transfusion requirements during nephrectomy for renal cell carcinoma. J Vasc Interv Radiol. 1993;4(6):727–31. DOI: 10.1016/s1051-0443(93)71958-2</mixed-citation><mixed-citation xml:lang="en">Bakal C.W., Cynamon J., Lakritz P.S., Sprayregen S. Value of preoperative renal artery embolization in reducing blood transfusion requirements during nephrectomy for renal cell carcinoma. J Vasc Interv Radiol. 1993;4(6):727–31. DOI: 10.1016/s1051-0443(93)71958-2</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zubairova L.D., Nabiullina R.M., Nagaswami C., Zuev Y.F., Mustafin I.G., Litvinov R.I., et al. Circulating microparticles alter formation, structure, and properties of fibrin clots. Sci Rep. 2015;5:17611. DOI: 10.1038/srep17611</mixed-citation><mixed-citation xml:lang="en">Zubairova L.D., Nabiullina R.M., Nagaswami C., Zuev Y.F., Mustafin I.G., Litvinov R.I., et al. Circulating microparticles alter formation, structure, and properties of fibrin clots. Sci Rep. 2015;5:17611. DOI: 10.1038/srep17611</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Bakke A., Gothlin J.H., Haukaas S.A., Kalland T. Augmentation of natural killer cell activity after arterial embolization of renal carcinomas. Cancer Res. 1982;42(9):3880–3.</mixed-citation><mixed-citation xml:lang="en">Bakke A., Gothlin J.H., Haukaas S.A., Kalland T. Augmentation of natural killer cell activity after arterial embolization of renal carcinomas. Cancer Res. 1982;42(9):3880–3.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Нагаева В.В., Кокорева Е.Г., Елисеев Е.В. Тканеспецифические антитела и продолжительность заболевания: диагностическое и прогностическое значение. Здравоохранение, образование и безопасность. 2015;(2):17–9.</mixed-citation><mixed-citation xml:lang="en">Nagaeva V.V., Kokoreva E.G., Eliseev E.V. Tissue-specific antibodies and duration of the disease: diagnostic and prognostic value. Healthcare, education and security. 2015;(2):17–9 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Boichuk S., Dunaev P., Galembikova A., Mustafin I., Valeeva E. Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinibresistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors. Anti-Cancer Drugs. 2018;29(6):549–59. DOI: 10.1097/CAD.0000000000000637</mixed-citation><mixed-citation xml:lang="en">Boichuk S., Dunaev P., Galembikova A., Mustafin I., Valeeva E. Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors. Anti-Cancer Drugs. 2018;29(6):549–59. DOI: 10.1097/CAD.0000000000000637</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Zyuz’kov G.N., Zhdanov V.V., Udut E.V., Miroshnichenko L.A., Polyakova T.Y., Stavrova L.A., et al. Strategy of pharmacological regulation of intracellular signal transduction in regeneration-competent cells. Bull Exp Biol Med. 2019;166(4):448–55. DOI: 10.1007/s10517-019-04370-x</mixed-citation><mixed-citation xml:lang="en">Zyuz’kov G.N., Zhdanov V.V., Udut E.V., Miroshnichenko L.A., Polyakova T.Y., Stavrova L.A., et al. Strategy of pharmacological regulation of intracellular signal transduction in regeneration-competent cells. Bull Exp Biol Med. 2019;166(4):448–55. DOI: 10.1007/s10517-019-04370-x</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Удалов Ю.Д., Гордиенко А.В., Самойлов А.С., Бахарев С.А. Предикторы развития фатальных осложнений у пациентов онкохирургического профиля. Здравоохранение, образование и безопасность. 2018;(2):66–75.</mixed-citation><mixed-citation xml:lang="en">Udalov Yu.D., Gordienko A.V., Samoilov A.S., Bakharev S.A. Predictors of development of fatal complications in the patients of the oncosurgery profile. Healthcare, education and security. 2018;(2):66–75 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Dygai A.M., Zyuz’kov G.N., Zhdanov V.V., Simanina E.V., Stavrova L.A., Udut E.V., et al. Effect of transplantation of peripheral blood mononuclears obtained using granulocytic colony-stimulating factor and hyaluronidase on regeneration of hemopoietic tissue during myelosuppression. Bull Exp Biol Med. 2009;148(1):120–5. DOI: 10.1007/s10517-009-0655-3</mixed-citation><mixed-citation xml:lang="en">Dygai A.M., Zyuz’kov G.N., Zhdanov V.V., Simanina E.V., Stavrova L.A., Udut E.V., et al. Effect of transplantation of peripheral blood mononuclears obtained using granulocytic colony-stimulating factor and hyaluronidase on regeneration of hemopoietic tissue during myelosuppression. Bull Exp Biol Med. 2009;148(1):120–5. DOI: 10.1007/s10517-009-0655-3</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
